Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 29 publications
Prediction of Anthracycline Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early-Stage Breast Cancer by the MammaPrint 70-Gene Signature for Patients Enrolled in the FLEX Study.
Journal: JCO precision oncology
Published: June 24, 2026
MammaPrint predicts chemotherapy benefit in HR+HER2- early breast cancer: FLEX Registry real-world data.
Journal: JNCI cancer spectrum
Published: April 22, 2025
Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 06, 2024
Home Visiting and Child Welfare Involvement: A Matched Comparison Group Study.
Journal: Child maltreatment
Published: July 30, 2024
Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis.
Journal: Cancer discovery
Published: July 28, 2022
The transition to parenthood in obstetrics: enhancing prenatal care for 2-generation impact.
Journal: American journal of obstetrics & gynecology MFM
Published: June 13, 2022
Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 29, 2021
School-Level Efforts to Address Sexual Health and Risky Sexual Behavior Among Students in Texas Alternative High Schools.
Journal: The Journal of school nursing : the official publication of the National Association of School Nurses
Published: August 26, 2020
"Mom, I'm Pregnant": The Adolescent Pregnancy Reveal.
Journal: The Social service review
Published: June 01, 2020
Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer.
Journal: Breast cancer research and treatment
Published: February 05, 2020
The influence of field-based training on caseworker turnover.
Journal: Children and youth services review
Published: January 01, 2020
Comutation of PIK3CA and TP53 in Residual Disease After Preoperative Anti-HER2 Therapy in ERBB2 (HER2)-Amplified Early Breast Cancer.
Journal: JCO precision oncology
Published: December 01, 2019
Last Updated: 09/26/2026